Silence Therapeutics Plc (SLNCF)
5.50
0.00 (0.00%)
USD |
OTCM |
Aug 21, 16:00
Silence Therapeutics Debt to Equity Ratio : 0.0029 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0029 |
| March 31, 2026 | 0.0028 |
| December 31, 2025 | 0.0026 |
| September 30, 2025 | 0.0025 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.0005 |
| September 30, 2024 | 0.0015 |
| June 30, 2024 | 0.0016 |
| March 31, 2024 | 0.0022 |
| Date | Value |
|---|---|
| December 31, 2023 | 0.016 |
| September 30, 2023 | 0.0158 |
| June 30, 2023 | 0.0297 |
| March 31, 2023 | 0.024 |
| December 31, 2022 | 0.0202 |
| September 30, 2022 | 0.0146 |
| June 30, 2022 | -0.011 |
| March 31, 2022 | 0.0226 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | 0.0332 |
| Mereo BioPharma Group Plc | 0.0359 |
| Compass Pathways Plc | 0.6462 |
| HemoGenyx Pharmaceuticals Plc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 106.41M |
| Total Liabilities (Quarterly) | 67.94M |
| Shareholders Equity (Quarterly) | 38.47M |
| Current Ratio | 7.416 |
| Net Debt Paydown Yield | -0.00% |